stars 1 stars 2 stars 3

Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.

View Top Employees from Kynexis
Website https://www.kynexistx.com
Employees 18 (8 on RocketReach)
Industry Biotechnology Research

Kynexis Questions

Jens Wendland is the Chief Medical Officer of Kynexis.

8 people are employed at Kynexis.

Top Kynexis Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users